Figure 1.
Synthesis of mineralized bone matrix in the osteoblastic-like cell line SaOS-2 under treatment with IMA (middle column, 1 µM) and NIL (1 µM, right-hand column) in comparison with untreated control (left-hand column): Hemofix-stained samples at different time points (day 0, 5, 10, 15 or 25) of incubation. Mineralized areas are represented by black areas. Representative pictures are shown (n=3). IMA, imatinib; NIL, nilotinib.
